Drug Trial Radar · NCT06680830
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 17, 2025
Primary completion
Dec 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Neuron23 Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Qiagen Manchester Limited; Roche Diagnostic Ltd.
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.
Conditions
- Parkinson Disease
- Parkinson
- Idiopathic Parkinson Disease
- Early Parkinson Disease (Early PD)
- Parkinson Disease, Idiopathic
Interventions
NEU-411Drug
NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity
PlaceboOther
Orally-administered matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Roche digital biomarker score using the Roche Parkinson's Disease application (v3.0) compared to placeboTime frame: From enrollment to the end of treatment at 52 weeks
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placeboTime frame: From enrollment to the end of study at 54 weeks
Locations
72 sites in 6 countries. Site status is shown where the registry gives one.
Banner Sun Health Research Institute
Sun City, Arizona · Recruiting
University of Arkansas
Little Rock, Arkansas · Recruiting
Neuro-Pain Medical Center
Fresno, California · Recruiting
University of California, Irvine
Irvine, California · Recruiting
University of California, Los Angeles
Los Angeles, California · Recruiting
Esperanza Clinical
Murrieta, California · Completed
Parkinson's Research Centers of America - Palo Alto
Palo Alto, California · Recruiting
Sutter Neuroscience Institute
Sacramento, California · Recruiting
University of Colorado - Anschutz Medical Campus
Aurora, Colorado · Recruiting
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Neurology One
Orlando, Florida · Recruiting
USF Parkinson's & Movement Disorders Clinic
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Augusta University
Augusta, Georgia · Recruiting
Northwestern Medical Group, Department of Neurology
Chicago, Illinois · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
University of Kentucky
Lexington, Kentucky · Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Recruiting
University of Maryland
Baltimore, Maryland · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Quest Research Institute
Farmington Hills, Michigan · Recruiting
Struthers Parkinson Center
Golden Valley, Minnesota · Recruiting
Cleveland Clinic
Las Vegas, Nevada · Recruiting
University of New Mexico
Albuquerque, New Mexico · Recruiting
Northwell Health
Manhasset, New York · Recruiting
Icahn School of Medicine at Mount Sinai/Mount Sinai West
New York, New York · Recruiting
Columbia University
New York, New York · Recruiting
University of Rochester
Rochester, New York · Recruiting
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma · Recruiting
Oregon Health & Science University (OHSU)
Portland, Oregon · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Vanderbilt University
Nashville, Tennessee · Recruiting
Neurology Consultants of Dallas PA
Dallas, Texas · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
The University of Texas Health Science Center at Houston
Houston, Texas · Recruiting
Central Texas Neurology Consultants
Round Rock, Texas · Recruiting
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.